SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
PD59-11 TARGETING BCL2 TO INCREASE ENZALUTAMIDE SENSITIVITY TO BETTER SUPPRESS PROSTATE CANCER PROGRESSION THROUGH ALTERING ARV7 PROTEIN DEGRADATION
作者
Hua Xu
出处
期刊:
The Journal of Urology
[Lippincott Williams & Wilkins]
日期:2020-04-01
卷期号:203 (Supplement 4)
链接
auajournals.org
doi.org
标识
DOI:10.1097/ju.0000000000000969.011
摘要
You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology III (PD59)1 Apr 2020PD59-11 TARGETING BCL2 TO INCREASE ENZALUTAMIDE SENSITIVITY TO BETTER SUPPRESS PROSTATE CANCER PROGRESSION THROUGH ALTERING ARV7 PROTEIN DEGRADATION Hua Xu* Hua Xu*Hua Xu* More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000969.011AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Androgen deprivation therapy (ADT) with antiandrogens targeting androgens/androgen receptor (AR) signaling is the standard used to treat prostate cancer in different clinical settings besides surgical treatment. However, most prostate cancer patients will eventually develop cancer progression despite castrate levels of testosterone, into castration resistant prostate cancer (CRPC). The recently developed antiandrogen, Enzalutamide, has reformed the standard of care for castration resistant prostate cancer patients. However, Enzalutamide resistance inevitably emerges despite success of Enzalutamide in prolonging castration resistant prostate cancer patients’ survival. Here we found that Enzalutamide resistant prostate cancer cells had higher BCL2 expression. We aimed to test whether targeting BCL2 would influence Enzalutamide sensitivity of prostate cancer and identify the potential mechanism. METHODS: The study was designed to target Enzalutamide induced BCL2 with inhibitor ABT263 and test Enzalutamide sensitivity in Enz-resistant prostate cancer cells by MTT assay. Cellular reactive oxygen species levels were detected with dihydroethidium staining, and in vitro deubiquitinating enzyme activity assay was used to evaluate ubiquitin specific protease 26 (USP26) activity. RESULTS: We retrospectively performed an RNA sequencing among 625 CRPC patients and 625 matched hormone-sensitive prostate cancer (HSPC) patients and revealed that BCL2 was significant increased in CRPC, which indicated that targeting BCL2 might be a potential option. BCL2 inhibitor, ABT263 could increase Enzalutamide sensitivity and increase the ubiquitination of androgen receptor (AR) and AR splice variant 7 (ARv7) and their ubiquitin/proteasome-dependent degradation in both Enzalutamide sensitive and Enzalutamide resistant prostate cancer cells. As BCL2 is a classical anti-apoptosis protein, we then tested the potential linkage of its anti-apoptotic activity to its ability to alter the AR and ARv7 expression. The results revealed that inhibition of BCL2 activity by ABT263 (with and without Enz treatment) resulted in cleaved-PARP expression in both EnzS1-C4-2 and EnzR1-C4-2 and EnzR3-CWR22Rv1 PCa cells, suggesting that ABT263 could promote PCa apoptosis. However, blocking apoptosis through inhibition of caspase activity with Z-VAD-FMK (pan-caspase inhibitor) failed to reverse the decrease of AR and ARv7 protein expression, suggesting that the apoptotic pathway was unlikely responsible for the decrease of AR and ARv7 expression. As BCL2 is a mitochondria protein that may alter the mitochondria function via modulating the ROS, we then tested weather ABT263 could function via altering the cellular ROS to decrease the AR and ARv7 expression to further influence Enzalutamide sensitivity. ABT263 treatment could significantly induce cellular ROS level in both EnzS1-C4-2 and EnzR1-C4-2 and EnzR3-CWR22Rv1 PCa cells. Elevated cellular reactive oxygen species levels might then inhibit USP26 activity to increase the ubiquitination of androgen receptor (AR) and AR splice variant 7 (ARv7) and their ubiquitin/proteasome-dependent degradation, which contributed to the increase of Enz sensitivity. In vivo mouse model also demonstrates that ABT263 will suppress the prostate cancer progression. CONCLUSIONS: This study demonstrated that targeting Enzalutamide induced BCL2 with inhibitor ABT263 could increase Enzalutamide sensitivity in both Enzalutamide sensitive and Enzalutamide resistant prostate cancer cells through induction of cellular reactive oxygen species levels and suppression of USP26 activity with a consequent increase of ubiquitin/proteasome-dependent degradation of AR and ARv7 protein expression. This preclinical study established the foundation to use ABT263 in combination with Enzalutamide to treat prostate cancer patients, especially those resistant to Enzalutamide. Source of Funding: National Natural Science Foundation of China (No. 81472377 and 81802570) © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1209-e1209 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hua Xu* More articles by this author Expand All Advertisement PDF downloadLoading ...
求助该文献
相关文献
暂未提供新的相关文献。
科研通智能强力驱动
Strongly Powered by AbleSci AI
我的文献求助列表
浏览历史
一分钟了解求助规则
|
捐赠本站
|
历史今天
更新
⚡
2026年影响因子、分区
已更新!
(2026-6-17)
更新
📰 新增『新锐期刊分区』
(2026-3-24)
更新
💬 新增更精细的自定义提醒设置
(2026-1-4)
新增
🕒 每天60秒读懂世界·精选全球要闻
(2026-1-2)
新增
PDF的下载单位、IP信息已删除
(2025-6-4)
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
宋艳芳
完成签到,获得积分
10
2秒前
快乐的幼丝
完成签到
,获得积分
0
2秒前
香蕉觅云
的
应助
被
大明
采纳,获得
10
3秒前
CHEN
完成签到
,获得积分
10
6秒前
驰骋
完成签到
,获得积分
10
7秒前
maple
完成签到
,获得积分
10
7秒前
阿冰
完成签到
,获得积分
10
8秒前
酷炫映阳
完成签到
,获得积分
10
9秒前
怡然的千儿
完成签到,获得积分
10
10秒前
大明
完成签到,获得积分
10
11秒前
harden9159
完成签到,获得积分
10
12秒前
斯文败类
上传了
应助文件
16秒前
仁仁仁
完成签到,获得积分
10
17秒前
灯座
完成签到,获得积分
10
19秒前
u雨
发布了新的
文献求助
10
20秒前
Voiceless
的
应助
被
Bin_Liu
采纳,获得
10
23秒前
不吃压力就是干
完成签到
,获得积分
10
23秒前
Lingeek
完成签到,获得积分
10
28秒前
霸气芫
完成签到
,获得积分
10
32秒前
Lingeek
上传了
应助文件
32秒前
betty2009
完成签到,获得积分
10
33秒前
饱满千兰
完成签到,获得积分
10
34秒前
科研通AI6.3
的
应助
被
u雨
采纳,获得
10
38秒前
王kk
完成签到
,获得积分
10
39秒前
哈哈哈
完成签到
,获得积分
10
41秒前
邓代容
完成签到
,获得积分
0
46秒前
奋斗诗云
完成签到
,获得积分
10
48秒前
irisyan
完成签到
,获得积分
10
50秒前
白云
完成签到
,获得积分
10
51秒前
难过的研究牲
完成签到
,获得积分
10
52秒前
大耳朵图图
完成签到
,获得积分
10
53秒前
孤狼
完成签到
,获得积分
10
57秒前
子良
完成签到
,获得积分
10
57秒前
xinxin
完成签到
,获得积分
10
58秒前
黑白
完成签到
,获得积分
10
58秒前
一诺相许
完成签到,获得积分
10
1分钟前
领导范儿
的
应助
被
文文
采纳,获得
10
1分钟前
xh
完成签到,获得积分
10
1分钟前
QwQ
完成签到
,获得积分
10
1分钟前
高兴的灰狼
完成签到,获得积分
20
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】
10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究
1700
The World Atlas of Wine 9th edition
1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)
800
John McDowells Bildungstheorie
800
Social Psychology in the Real World
600
八旗制度の研究
600
热门求助领域
(近24小时)
化学
材料科学
医学
生物
纳米技术
计算机科学
工程类
有机化学
化学工程
生物化学
物理
复合材料
内科学
催化作用
光电子学
人工智能
细胞生物学
无机化学
物理化学
数学
热门帖子
关注
科研通微信公众号,转发送积分
8180068
求助须知:如何正确求助?哪些是违规求助?
9570224
关于积分的说明
21808724
捐赠科研通
7776054
什么是DOI,文献DOI怎么找?
3433261
关于科研通互助平台的介绍
2557425
邀请新用户注册赠送积分活动
2479012
今日热心研友
水煮电吹风
719
220
fantasy
101
575
Nole
54
940
嘻嘻哈哈
94
400
Maestro_S
49
430
学霸业
39
410
OK
780
吃葡萄不吐葡萄皮
31
330
369ninja
32
260
煎饼煎饼
510
忧心的曼凝
48
GingerF
7
390
null
440
CAOHOU
27
150
xinyuanjia
19
220
华无剑
16
160
极限001
320
zilicai
17
120
无极微光
12
150
loii
15
110
注:热心度 = 本日应助数 + 本日被采纳获取积分÷10